CH652927A5 - Pharmazeutische zusammensetzung, enthaltend ein dibenzocycloheptadien-antidepressivum und codergocrin. - Google Patents

Pharmazeutische zusammensetzung, enthaltend ein dibenzocycloheptadien-antidepressivum und codergocrin. Download PDF

Info

Publication number: CH652927A5
Authority: CH; Switzerland
Prior art keywords: active ingredient; composition according; codergocrin; pharmaceutically acceptable; dibenzocycloheptadiene
Prior art date: 1982-03-22

Application number

CH1296/83A

Other languages

German (de)

English (en)

Inventor

Robert W Griffith

Jack Singer

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-22

Filing date

1983-03-10

Publication date

1985-12-13

1983-03-10 Application filed by Sandoz Ag filed Critical Sandoz Ag

1985-12-13 Publication of CH652927A5 publication Critical patent/CH652927A5/de

Links

230000001430 anti-depressive effect Effects 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
PJQCANLCUDUPRF-UHFFFAOYSA-N dibenzocycloheptene Chemical compound C1CC2=CC=CC=C2CC2=CC=CC=C12 PJQCANLCUDUPRF-UHFFFAOYSA-N 0.000 title description 4
239000004480 active ingredient Substances 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 21
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 11
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 8
239000000935 antidepressant agent Substances 0.000 claims description 8
229940005513 antidepressants Drugs 0.000 claims description 8
229960001158 nortriptyline Drugs 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
239000012458 free base Substances 0.000 claims description 6
208000024827 Alzheimer disease Diseases 0.000 claims description 4
206010039966 Senile dementia Diseases 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
230000000694 effects Effects 0.000 description 9
239000002775 capsule Substances 0.000 description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
208000020401 Depressive disease Diseases 0.000 description 5
239000000725 suspension Substances 0.000 description 4
-1 3-methylaminopropylidene Chemical group 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
SHAYBENGXDALFF-UHFFFAOYSA-N Nortriptyline hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C(=CCC[NH2+]C)C2=CC=CC=C21 SHAYBENGXDALFF-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical class CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940040520 ergoloid mesylates Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
229960003039 nortriptyline hydrochloride Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CH1296/83A 1982-03-22 1983-03-10 Pharmazeutische zusammensetzung, enthaltend ein dibenzocycloheptadien-antidepressivum und codergocrin. CH652927A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36046382A	1982-03-22	1982-03-22

Publications (1)

Publication Number	Publication Date
CH652927A5 true CH652927A5 (de)	1985-12-13

Family

ID=23418055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH1296/83A CH652927A5 (de)	1982-03-22	1983-03-10	Pharmazeutische zusammensetzung, enthaltend ein dibenzocycloheptadien-antidepressivum und codergocrin.

Country Status (18)

Country	Link
JP (1)	JPS58174317A (fr)
AU (1)	AU1262283A (fr)
BE (1)	BE896170A (fr)
CA (1)	CA1197465A (fr)
CH (1)	CH652927A5 (fr)
DE (1)	DE3308855A1 (fr)
FR (1)	FR2527077B1 (fr)
GB (1)	GB2116843B (fr)
GR (1)	GR77165B (fr)
HU (1)	HU190714B (fr)
IL (1)	IL68184A (fr)
IT (1)	IT1163156B (fr)
NL (1)	NL8300986A (fr)
NZ (1)	NZ203632A (fr)
PH (1)	PH22086A (fr)
PT (1)	PT76417B (fr)
SE (1)	SE8301530L (fr)
ZA (1)	ZA832005B (fr)

1983
- 1983-03-10 CH CH1296/83A patent/CH652927A5/de not_active IP Right Cessation
- 1983-03-12 DE DE19833308855 patent/DE3308855A1/de not_active Withdrawn
- 1983-03-16 BE BE1/10740A patent/BE896170A/fr not_active IP Right Cessation
- 1983-03-16 FR FR8304428A patent/FR2527077B1/fr not_active Expired
- 1983-03-18 NL NL8300986A patent/NL8300986A/nl not_active Application Discontinuation
- 1983-03-18 JP JP58044528A patent/JPS58174317A/ja active Pending
- 1983-03-18 GR GR70832A patent/GR77165B/el unknown
- 1983-03-21 SE SE8301530A patent/SE8301530L/xx not_active Application Discontinuation
- 1983-03-21 PT PT76417A patent/PT76417B/pt unknown
- 1983-03-21 HU HU83934A patent/HU190714B/hu unknown
- 1983-03-21 NZ NZ203632A patent/NZ203632A/en unknown
- 1983-03-21 IT IT20186/83A patent/IT1163156B/it active
- 1983-03-21 IL IL68184A patent/IL68184A/xx unknown
- 1983-03-21 CA CA000424059A patent/CA1197465A/fr not_active Expired
- 1983-03-21 GB GB08307751A patent/GB2116843B/en not_active Expired
- 1983-03-21 AU AU12622/83A patent/AU1262283A/en not_active Abandoned
- 1983-03-22 ZA ZA832005A patent/ZA832005B/xx unknown
- 1983-06-01 PH PH28998A patent/PH22086A/en unknown

Also Published As

Publication number	Publication date
AU1262283A (en)	1983-09-29
HU190714B (en)	1986-10-28
IT8320186A0 (it)	1983-03-21
PT76417B (en)	1985-12-16
SE8301530L (sv)	1983-09-23
CA1197465A (fr)	1985-12-03
FR2527077A1 (fr)	1983-11-25
FR2527077B1 (fr)	1986-08-22
NL8300986A (nl)	1983-10-17
IL68184A0 (en)	1983-06-15
SE8301530D0 (sv)	1983-03-21
GB8307751D0 (en)	1983-04-27
ZA832005B (en)	1984-11-28
GR77165B (fr)	1984-09-10
IL68184A (en)	1986-04-29
GB2116843B (en)	1986-01-15
PT76417A (en)	1983-04-01
IT1163156B (it)	1987-04-08
JPS58174317A (ja)	1983-10-13
BE896170A (fr)	1983-09-16
DE3308855A1 (de)	1983-09-29
NZ203632A (en)	1986-09-10
PH22086A (en)	1988-05-20
GB2116843A (en)	1983-10-05

Legal Events

Date	Code	Title	Description
1987-11-30	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE69710390T2 (de)	2002-08-14	Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren
DE3586545T2 (de)	1993-03-04	Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
DE69900249T2 (de)	2002-06-13	Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69034149T2 (de)	2004-09-30	Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen
DE69012261T2 (de)	1995-01-12	Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
EP0180785B1 (fr)	1989-07-19	Médicament contenant une combinaison de Nitrendipine et d'Enalaprile et procédé pour sa fabrication
EP0752246A2 (fr)	1997-01-08	Agonistes des récepteurs kappa aux opioides pour des maladies inflammatoires de l'intestin
DE69908421T2 (de)	2004-03-18	Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol
DE69226447T2 (de)	1999-04-22	NMDA Antagonisten
EP0224810A1 (fr)	1987-06-10	Préparation antihypertensive contenant un mélange
DE60123528T2 (de)	2007-02-15	Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
DE2721259C2 (fr)	1988-04-28
EP0293714B1 (fr)	1991-06-05	Combinaisons de produits à action antidépressive
DE69004529T2 (de)	1994-02-24	Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
DE60122252T2 (de)	2007-07-05	Verfahren zur behandlung von neurodegeneration
DE2658500C2 (de)	1986-10-09	Pharmazeutische Präparate mit kardioprotektiver Wirkung
EP0665014B1 (fr)	1997-09-03	Dérivés de 3-benzoyl-3,7-diazabicyclo(3,3,1)nonane présentant une activité antiarrhythmique
DE602004011486T2 (de)	2009-01-15	Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas
CH652927A5 (de)	1985-12-13	Pharmazeutische zusammensetzung, enthaltend ein dibenzocycloheptadien-antidepressivum und codergocrin.
CH649918A5 (de)	1985-06-28	Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
EP0013252B1 (fr)	1987-09-23	Agent de réduction du rythme cardiaque
DE69710526T2 (de)	2002-10-02	Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen
DE2128730A1 (de)	1971-12-16	Mittel zur Kompensierung eines Dopaminmangels im Gehirn
DE4217396A1 (de)	1993-12-02	Metrifonat enthaltendes Arzneimittel
EP0241428B1 (fr)	1992-03-18	Utilisation des composés du 2-aminoalkyl-5-pyridinol comme nootropiques et antidépressants